At long last, the FDA has authorized 23andMe to market health-related genetic testing. It's good news, but the impact of this is minimal for the time being. This specific authorization is for analysis of a single disease, but this "important first step" paves the way for the full suite of DNA analysis to return to the Mountain View-based genetics company.
from ExtremeTech http://ift.tt/1EnuaC7
ليست هناك تعليقات:
إرسال تعليق